期刊
BRITISH JOURNAL OF PSYCHIATRY
卷 207, 期 1, 页码 46-51出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1192/bjp.bp.114.154047
关键词
-
类别
资金
- NARSAD Young Investigator Award from the Brain and Behavior Research Foundation
- AHRQ CERTs award for the Rutgers Center for Education and Research on Mental Health Therapeutics [U19 HS021112-02]
- New York State Psychiatric Institute
Background Lithium inhibits glycogen synthase kinase-3, an enzyme implicated in the pathogenesis of dementia. Aims To examine the association of lithium and dementia risk in a large claims-based US cohort of publicly insured older adults with bipolar disorder. Method The cohort included individuals >= 50 years diagnosed with bipolar disorder who did not receive dementia-related services during the prior year. Each follow-up day was classified by past-year cumulative duration of lithium use (0, 1-60, 61-300 and 301-365 days). Dementia diagnosis was the study outcome. Anticonvulsants commonly used as mood stabilisers served as a negative control. Results Compared with non-use, 301-365 days of lithium exposure was associated with significantly reduced dementia risk (hazard ratio (HR)=0.77, 95% Cl 0.60-0.99). No corresponding association was observed for shorter lithium exposures (HR= 1.04, 95% Cl 0.83-1.31 for 61-300 days; HR= 1.07, 95% Cl 0.67-1.71 for 1-60 days) or for any exposure to anticonvulsants. Conclusions Continuous lithium treatment may reduce dementia risk in older adults with bipolar disorder. Copyright and usage (C) The Royal College of Psychiatrists 2015.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据